GENOR BIOPHARMA DL-00002 Net Asset Momentum
GENOR BIOPHARMA DL-00002 net asset momentum. GENOR BIOPHARMA DL-00002 (67N0) recorded a net asset momentum of -3.3% as of December 2024, with net assets of €1.15 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore GENOR BIOPHARMA DL-00002 cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of GENOR BIOPHARMA DL-00002 (2021–2024)
Net asset momentum of GENOR BIOPHARMA DL-00002 from 2021 to 2024. This chart tracks GENOR BIOPHARMA DL-00002's year-over-year net asset growth across 4 annual reporting periods from 2021 to 2024. The most recent momentum reading is -3.3%, with net assets of €1.15 Billion EUR as of December 2024. See what is GENOR BIOPHARMA DL-00002's book value for net asset value and shareholders' equity analysis.
GENOR BIOPHARMA DL-00002 Net Asset Momentum by Year (2021–2024)
GENOR BIOPHARMA DL-00002 net asset momentum by year from 2021 to 2024. The table below shows the complete annual net asset history for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see GENOR BIOPHARMA DL-00002 market cap and net worth.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | €1.15 Billion | €1.29 Billion | €138.05 Million | ▼ -3.3% |
| 2023 | €1.19 Billion | €1.45 Billion | €256.18 Million | ▼ -34.0% |
| 2022 | €1.81 Billion | €2.12 Billion | €309.87 Million | ▼ -27.6% |
| 2021 | €2.49 Billion | €2.86 Billion | €369.73 Million | — |